These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28197316)

  • 21. Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders.
    Guan HP; Xiong Y
    Front Pharmacol; 2022; 13():1043828. PubMed ID: 36386134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GPR40-Mediated G
    Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
    Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linoleic acid activates GPR40/FFA1 and phospholipase C to increase [Ca2+]i release and insulin secretion in islet beta-cells.
    Zhou YJ; Song YL; Zhou H; Li Y
    Chin Med Sci J; 2012 Mar; 27(1):18-23. PubMed ID: 22734209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of Glucose-stimulated Insulin Secretion by the GPR40-PLC-TRPC Pathway in Pancreatic β-Cells.
    Yamada H; Yoshida M; Ito K; Dezaki K; Yada T; Ishikawa SE; Kakei M
    Sci Rep; 2016 May; 6():25912. PubMed ID: 27180622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
    Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
    J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.
    Christiansen E; Hansen SV; Urban C; Hudson BD; Wargent ET; Grundmann M; Jenkins L; Zaibi M; Stocker CJ; Ullrich S; Kostenis E; Kassack MU; Milligan G; Cawthorne MA; Ulven T
    ACS Med Chem Lett; 2013 May; 4(5):441-445. PubMed ID: 23687558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
    Christiansen E; Due-Hansen ME; Urban C; Merten N; Pfleiderer M; Karlsen KK; Rasmussen SS; Steensgaard M; Hamacher A; Schmidt J; Drewke C; Petersen RK; Kristiansen K; Ullrich S; Kostenis E; Kassack MU; Ulven T
    ACS Med Chem Lett; 2010 Oct; 1(7):345-9. PubMed ID: 24900217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1.
    Yang J; Gu E; Yan T; Shen D; Feng B; Tang C
    Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of GPR40 Agonists for Type 2 Diabetes.
    Liu JJ; Wang Y; Ma Z; Schmitt M; Zhu L; Brown SP; Dransfield PJ; Sun Y; Sharma R; Guo Q; Zhuang R; Zhang J; Luo J; Tonn GR; Wong S; Swaminath G; Medina JC; Lin DC; Houze JB
    ACS Med Chem Lett; 2014 May; 5(5):517-21. PubMed ID: 24900872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
    Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
    Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
    Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
    PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.
    Song F; Lu S; Gunnet J; Xu JZ; Wines P; Proost J; Liang Y; Baumann C; Lenhard J; Murray WV; Demarest KT; Kuo GH
    J Med Chem; 2007 Jun; 50(12):2807-17. PubMed ID: 17500511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.
    Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
    Am J Physiol Endocrinol Metab; 2013 Mar; 304(6):E668-76. PubMed ID: 23341496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids.
    Del Guerra S; Bugliani M; D'Aleo V; Del Prato S; Boggi U; Mosca F; Filipponi F; Lupi R
    Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):22-5. PubMed ID: 19758793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.